Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 12,500 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. This represents a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, July 8th, Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.85, for a total transaction of $807,800.00.
• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00.

Bicara Therapeutics Stock Performance

Shares of BCAX traded up $0.87 on Wednesday, reaching $24.63. The stock had a trading volume of 810,259 shares, compared to its average volume of 608,476. Bicara Therapeutics Inc. has a 12-month low of $10.30 and a 12-month high of $30.99. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -8.86 and a beta of -0.75. The company has a 50-day simple moving average of $25.90 and a 200-day simple moving average of $21.69.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). On average, analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current fiscal year.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics’ Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors have recently made changes to their positions in the business. Deutsche Bank AG raised its stake in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after acquiring an additional 1,171 shares during the period. Legal & General Group Plc increased its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Mariner LLC raised its position in shares of Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after purchasing an additional 1,902 shares during the period. Invesco Ltd. raised its position in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares during the period. Finally, Quantinno Capital Management LP lifted its stake in shares of Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after buying an additional 2,447 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Mizuho lifted their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wells Fargo & Company boosted their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Finally, The Goldman Sachs Group raised their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.73.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.